LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Center
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CDMO
      • Quality System
      • CDMO Service
      • Quality Control
      • Global CDMO
      • CDMO Inquiries
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • CDMO Inquiries
    • IR Inquiries

U.S. ABC News gave intensified coverage on ‘CARTISTEM’

2015/05/20
STEM CELL THERAPEUTIC

U.S. ABC Broadcasting’s Boston regional channel (WCVB-TV) gave intensified coverage on ‘CARTISTEM®’, which is the cartilage regenerating stem cell medicine of MEDIPOST.

MEDIPOST announced that ‘NEW AT 11’ which is the major news program of ABC Broadcasting’s Boston regional channel, gave intensified coverage on the effectiveness and merits of ‘CARTISTEM®’, clinical test status in U.S and the experience of the test subjects etc. on May 19 (Korean time)

This day’s news introduced the decision and subsequent progress by a sports-loving U.S. man in his thirties to take clinical treatment of ‘CARTISTEM®’ rather than operation of artificial joint.

Also the program reported that “’CARTISTEM®’ treatment takes shorter period in recovery vis-à-vis other treatments, regenerates strong cartilage, and gives better vitality after treatment with less pain” quoting the statement by professor A. Gomoll who is the doctor in charge of the clinical test at Brigham & Women Hospital and the test subject respectively..

Also the program explained the status of cartilage of the test subject before ‘CARTISTEM®’ treatment by arthroscope and MRI (magnetic resonance imaging) photos, and broadcast the operation, recovery process and the fundamental of treatment etc.

VIEW LIST

Related News

MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelera…
2024/12/06
MEDIPOST Completes Administration for Phase 3 Clinical Trial…
2024/11/22
MEDIPOST Affiliate OmniaBio Hosts Opening Ceremony for New C…
2024/10/21
MEDIPOST Discusses CARTISTEM® Partnerships and Licensing Opp…
2024/10/14

Latest News

MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelera…
2024/12/06
MEDIPOST Completes Administration for Phase 3 Clinical Trial…
2024/11/22
MEDIPOST Affiliate OmniaBio Hosts Opening Ceremony for New C…
2024/10/21
MEDIPOST Discusses CARTISTEM® Partnerships and Licensing Opp…
2024/10/14
MEDIPOST’s CARTISTEM® Reaches Milestone of treating 30,000 P…
2024/06/24

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

Latest News

MEDIPOST Recruits Local Experts to U.S.…2024.12.06
MEDIPOST Completes Administration for Ph…2024.11.22
MEDIPOST Affiliate OmniaBio Hosts Openin…2024.10.21
MEDIPOST Discusses CARTISTEM® Partnershi…2024.10.14
MEDIPOST’s CARTISTEM® Reaches Milestone…2024.06.24

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST